At the beginning, epidermal growth factor receptor (EGFR)- and human epidermal growth factor receptor 2 (Her2)-targeted NIR-PIT agents were developed and then expanded to target diverse cancer cell surface antigens such as epithelial cell adhesion molecule (EpCAM), program death ligand 1 (PD-L1), prostate-specific membrane antigen (PMSA), cluster of differentiation (CD)44, CD47, CD20, CD25, and CD29 by using mAb and their fragments.13 The gene discussed is EGFR; the disease is cancer.